advertisement
Abstract #22163 Published in IGR 10-4
Pharmacogenetics of ophthalmic topical β-blockers
Sidjanin DJ; McCarty CA; Patchett R; Smith E; Wilke RAPersonalized Medicine 2008; 5: 377-385
Glaucoma is the second leading cause of blindness worldwide. The primary glaucoma risk factor is elevated intraocular pressure. Topical β-blockers are affordable and widely used to lower intraocular pressure. Genetic variability has been postulated to contribute to interpersonal differences in efficacy and safety of topical β-blockers. This review summarizes clinically significant polymorphisms that have been identified in the β-adrenergic receptors (ADRB1, ADRB2 and ADRB3). The implications of polymorphisms in CYP2D6 are also discussed. Although the candidate-gene approach has facilitated significant progress in our understanding of the genetic basi5 of glaucoma treatment response, most drug responses involve a large number of genes, each containing multiple polymorphisms. Genome-wide association studies may yield a more comprehensive set of polymorphisms associated with glaucoma outcomes. An understanding of the genetic mechanisms associated with variability in individual responses to topical β-blockers may advance individualized treatment at a lower cost.
Dr. D.J. Sidjanin, Medical College of Wisconsin, Department of Cell Biology Neurobiology and Anatomy, Milwaukee, WI, USA. dsidjani@mcw.edu
